Pure sustained dichroa ferbrifuga alkone formulation
OwnerXiao Qi Wanginventor
Life of this patent
Estimating the term…
Abstract
Now is provided a new sustained release drug preparation comprising such an inclusion complex of a medical compound with dichroa febrifuga alkone derivative (DFAD), which sustains or retards the dissolution and release of the DFAD at a controlled rate from the inclusion complex and hence from the drug preparation containing the DFAD, so as to maintain the concentration of the DFAD in blood at an effective level for prolonged time.
Claims6
A pure sustained release of dichroa ferbrifuga alkone derivative (DFAD). Composition comprising DFAD—containing micropellets having an surface thereof a coating of a pharmaceutically acceptable agent—thylcellulose in a micropellets.
The Pure Sustained Release Dichroa Ferbrifuga Alkone Formulation comprising:
- DFAD 99% by weight and ethylcellulose 1% by weight.
A process for producing DFAD comprising:
- (a) 1 KG of micronized DFAD were dispersed in 3.5 KG of sugar was placed in suspension and mix;
- (b) The DFAD is coated onto the sugar seed;
- (c) The resulting DFAD coated sugar seeds are then coated with a pharmaceutically acceptable waterinsoluble system such as ethylcellulose, cellulose acetate butyrate or cellulose triacetate, with ethyl cellulose preferred;
- (d) This coating enables release of the DFAD. The average diameter of each of the finished micropellets is about 0.4 to 0.6 mm, preferably about 0.5 mm;
- (e) This provides a coating with a sufficient amount of channels to enable the DFAD to be released;
- (f) The pellets were screened;
- and
- (g) The final coated products containing an ethylcellulose coating level of 1% was prepared. The pellets were dried under vacuum.
Dependencies are inferred from the claim text.